The FDA has accepted for priority review a supplemental biologics license application (sBLA) for teplizumab-mzwv (Tzield; Sanofi) that seeks to expand the current age indication from 8 years and older …
Copyright MatchingDonors.com©️ 2025 All rights reserved.